X-108626300-G-T
Variant summary
Our verdict is Pathogenic. The variant received 19 ACMG points: 19P and 0B. PM1PM2PM5PP2PP3_StrongPP5_Very_Strong
The NM_033380.3(COL4A5):c.3197G>T(p.Gly1066Val) variant causes a missense change involving the alteration of a conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. G1066D) has been classified as Pathogenic.
Frequency
Consequence
NM_033380.3 missense
Scores
Clinical Significance
Conservation
Publications
- Alport syndromeInheritance: XL Classification: DEFINITIVE Submitted by: ClinGen, G2P
- X-linked Alport syndromeInheritance: XL Classification: DEFINITIVE, STRONG, SUPPORTIVE Submitted by: PanelApp Australia, Genomics England PanelApp, Myriad Women’s Health, Orphanet, Labcorp Genetics (formerly Invitae)
Genome browser will be placed here
ACMG classification
Our verdict: Pathogenic. The variant received 19 ACMG points.
Transcripts
RefSeq
Ensembl
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | TSL | MANE | Protein | Appris | UniProt | 
|---|---|---|---|---|---|---|---|---|---|---|
| COL4A5 | ENST00000328300.11 | c.3197G>T | p.Gly1066Val | missense_variant | Exon 36 of 53 | 1 | NM_033380.3 | ENSP00000331902.7 | ||
| COL4A5 | ENST00000483338.1 | c.2021G>T | p.Gly674Val | missense_variant | Exon 20 of 20 | 1 | ENSP00000495685.1 | |||
| COL4A5 | ENST00000361603.7 | c.3197G>T | p.Gly1066Val | missense_variant | Exon 36 of 51 | 2 | ENSP00000354505.2 | |||
| COL4A5 | ENST00000505728.1 | c.428G>T | p.Gly143Val | missense_variant | Exon 4 of 5 | 3 | ENSP00000424137.1 | 
Frequencies
GnomAD3 genomes  
GnomAD4 exome Cov.: 30 
GnomAD4 genome  
ClinVar
Submissions by phenotype
not provided    Pathogenic:2 
For these reasons, this variant has been classified as Pathogenic. This sequence change replaces glycine with valine at codon 1066 of the COL4A5 protein (p.Gly1066Val). The glycine residue is highly conserved and there is a moderate physicochemical difference between glycine and valine. This variant is not present in population databases (ExAC no frequency). This variant has not been reported in the literature in individuals with COL4A5-related conditions. ClinVar contains an entry for this variant (Variation ID: 804587). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt COL4A5 protein function. This variant disrupts the p.Gly1066 amino acid residue in COL4A5. Other variant(s) that disrupt this residue have been observed in individuals with COL4A5-related conditions (PMID: 11223851, 8940267, Invitae), which suggests that this may be a clinically significant amino acid residue. This variant disrupts the triple helix domain of COL4A5. Glycine residues within the Gly-Xaa-Yaa repeats of the triple helix domain are required for the structure and stability of fibrillar collagens (PMID: 7695699, 8218237, 19344236). In COL4A5, missense variants at these glycine residues are significantly enriched in individuals with disease (PMID: 23720012, 27627812) compared to the general population (ExAC). -
The variant disrupts a glycine residue in the canonical Gly-X-Y repeats of the triple helix domain, which are required for stability and structure of this protein. Therefore it is expected to severely affect the function of the protein. Found in at least one symptomatic patient, and not found in general population data. -
COL4A5-related disorder    Pathogenic:1 
The COL4A5 c.3197G>T variant is predicted to result in the amino acid substitution p.Gly1066Val. To our knowledge, this variant has not been reported in the literature or in a large population database, indicating this variant is rare. The p.Gly1066 residue resides in the triple-helical region (residues 42 – 1456) of the COL4A5 protein (uniprot.org). The majority of pathogenic variants in COL4A5 substitute a glycine residue to a bulkier amino acid in the triple-helical domain (Hudson et al. 1993. PubMed ID: 8253711; https://www.ncbi.nlm.nih.gov/books/NBK1207/). Alternate nucleotide changes affecting the same amino acid (p.Gly1066Ser, p.Gly1066Arg, p.Gly1066Ala) have been reported to be pathogenic for Alport syndrome (Martin et al. 1998. PubMed ID: 9848783; Knebelmann et al. 1996. PubMed ID: 8940267; Barker et al. 2001. PubMed ID: 11223851). This variant is interpreted as likely pathogenic. -
X-linked Alport syndrome    Pathogenic:1 
- -
Computational scores
Source: 
Splicing
 Find out detailed SpliceAI scores and Pangolin per-transcript scores at